These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10122506

  • 1. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS, Garabedian-Ruffalo SM.
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [Abstract] [Full Text] [Related]

  • 2. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A, Palau E, Puerro M, Vargas E, Picazo JJ.
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [Abstract] [Full Text] [Related]

  • 3. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ.
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [Abstract] [Full Text] [Related]

  • 4. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L, Encinas MP, Morín LS, Vilches P, Gutiérrez N, García-Sanz R, Caballero D, Hurlé AD.
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [Abstract] [Full Text] [Related]

  • 5. Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues.
    Craven PC.
    Hosp Formul; 1993 Jan; 28 Suppl 1():41-5. PubMed ID: 10123838
    [Abstract] [Full Text] [Related]

  • 6. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C, Miró JM, Tuset M, Claramonte J, Gomar C, Gotsens R, Gómez B, Suárez S, Abellana R, Ascaso C, Cartaña R, Rodríguez E, Asenjo M, Carné X, Trilla A, Marco F, Gómez J, Brunet M, Pomar JL, Gatell JM, Ribas J.
    Med Clin (Barc); 2000 Jan; 114 Suppl 3():54-61. PubMed ID: 10994565
    [Abstract] [Full Text] [Related]

  • 7. Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage.
    Rybak MJ, Allen R, Arnow P, Craven PC, Freeman R, Grüneberg RN, Korin J, Nightingale CH, Rubinstein E, Schaison GS.
    Hosp Formul; 1993 Jan; 28 Suppl 1():62-8. PubMed ID: 10123844
    [No Abstract] [Full Text] [Related]

  • 8. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM, Bryson HM.
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of teicoplanin and ceftriaxone: a once-daily antibiotic regimen.
    Schaison GS.
    Hosp Formul; 1993 Jan; 28 Suppl 1():20-2. PubMed ID: 10123833
    [Abstract] [Full Text] [Related]

  • 10. Are glycopeptides still appropriate and convenient for empiric use?
    Gonzalez-Ruiz A, Richardson J.
    J Chemother; 2008 Oct; 20(5):531-41. PubMed ID: 19028614
    [Abstract] [Full Text] [Related]

  • 11. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R, Paganini H, Gómez S, Casimir L, Stamboulian D.
    Medicina (B Aires); 2002 Oct; 62 Suppl 2():48-51. PubMed ID: 12481489
    [Abstract] [Full Text] [Related]

  • 12. [The efficacy of intraventricularly administered vancomycin in the case of central nervous system infection caused by enterococcus faecalis].
    Czaban SL, Lebkowski WJ, Krajewski JP, Borkowski J.
    Wiad Lek; 2002 Oct; 55(9-10):617-25. PubMed ID: 12607418
    [Abstract] [Full Text] [Related]

  • 13. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagacé-Wiens PR, Rubinstein E, Hoban DJ, Karlowsky JA.
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [Abstract] [Full Text] [Related]

  • 14. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.
    Sancar AA, Yegenoglu S, de Vries R, Postma MJ, Simsek N, Pechlivanoglou P, Unal S.
    Pharm World Sci; 2008 Dec; 30(6):916-23. PubMed ID: 18803030
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Linezolid Pediatric Study Group.
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Non-inpatient use of teicoplanin.
    Nathwani D.
    Int J Clin Pract; 1998 Aug; 52(8):577-81. PubMed ID: 10622058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.